» Articles » PMID: 38685009

Hepatitis C Virus Subtype Diversity and Transmission Clusters Characteristics Among Drug Users in Zhuhai, South China

Overview
Journal BMC Infect Dis
Publisher Biomed Central
Date 2024 Apr 29
PMID 38685009
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hepatitis C virus (HCV) infection poses a major public health challenge globally, especially among injecting drug users. China has the world's largest burden of HCV infections. However, little is known about the characteristics of transmission networks among drug user populations. This study aims to investigate the molecular epidemiology and transmission characteristics of HCV infections among drug users in Zhuhai, a bustling port city connecting Mainland China and its Special Administrative Regions.

Methods: Participants enrolled in this study were drug users incarcerated at Zhuhai's drug rehabilitation center in 2015. Their sociodemographic and behavioral information, including gender, promiscuity, drug use method, and so forth, was collected using a standardized questionnaire. Plasmas separated from venous blood were analyzed for HCV infection through ELISA and RT-PCR methods to detect anti-HCV antibodies and HCV RNA. The 5'UTR fragment of the HCV genome was amplified and further sequenced for subtype identifications and phylogenetic analysis. The phylogenetic tree was inferred using the Maximum Likelihood method based on the Tamura-Nei model, and the transmission cluster network was constructed using Cytoscape3.8.0 software with a threshold of 0.015. Binary logistic regression models were employed to assess the factors associated with HCV infection.

Results: The overall prevalence of HCV infection among drug users was 44.37%, with approximately 19.69% appearing to clear the HCV virus successfully. Binary logistic regression analysis revealed that those aged over 40, engaging in injecting drug use, and being native residents were at heightened risk for HCV infection among drug user cohorts. The predominant HCV subtypes circulating among those drug users were 6a (60.26%), followed by 3b (16.7%), 3a (12.8%), 1b (6.41%) and 1a (3.85%), respectively. Molecular transmission network analysis unveiled the presence of six transmission clusters, with the largest propagation cluster consisting of 41 individuals infected with HCV subtype 6a. Furthermore, distinct transmission clusters involved eight individuals infected with subtype 3b and seven with subtype 3a were also observed.

Conclusion: The genetic transmission networks revealed a complex transmission pattern among drug users in Zhuhai, emphasizing the imperative for a targeted and effective intervention strategy to mitigate HCV dissemination. These insights are pivotal for shaping future national policies on HCV screening, treatment, and prevention in port cities.

Citing Articles

Asian Perspective on Hepatitis B Virus and Hepatitis C Virus Elimination.

Kaewdech A, Charatcharoenwitthaya P, Piratvisuth T Viruses. 2025; 17(1.

PMID: 39861823 PMC: 11768638. DOI: 10.3390/v17010034.

References
1.
Shier M, El-Wetidy M, Ali H, Al-Qattan M . Characterization of hepatitis C virus genotypes by direct sequencing of HCV 5'UTR region of isolates from Saudi Arabia. PLoS One. 2014; 9(8):e103160. PMC: 4123900. DOI: 10.1371/journal.pone.0103160. View

2.
Bao Y, Liu Z . Systematic review of HIV and HCV infection among drug users in China. Int J STD AIDS. 2009; 20(6):399-405. DOI: 10.1258/ijsa.2008.008362. View

3.
Martinez M, Franco S . Therapy Implications of Hepatitis C Virus Genetic Diversity. Viruses. 2021; 13(1). PMC: 7824680. DOI: 10.3390/v13010041. View

4.
Tang Q, Chen Z, Li H, Zhang L, Peng M, Zeng Y . Molecular epidemiology of hepatitis C virus genotypes in different geographical regions of Chinese mainland and a phylogenetic analysis. Infect Dis Poverty. 2023; 12(1):66. PMC: 10331966. DOI: 10.1186/s40249-023-01106-y. View

5.
Bartlett S, Wertheim J, Bull R, Matthews G, Lamoury F, Scheffler K . A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies. J Viral Hepat. 2016; 24(5):404-411. PMC: 5400687. DOI: 10.1111/jvh.12652. View